{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:26:52Z","timestamp":1770276412023,"version":"3.49.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"CANVAS"},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.vaccine.2018.02.068","type":"journal-article","created":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T10:09:05Z","timestamp":1519639745000},"page":"3397-3405","source":"Crossref","is-referenced-by-count":37,"title":["WHO\/IVI global stakeholder consultation on group A Streptococcus vaccine development: Report from a meeting held on 12\u201313 December 2016"],"prefix":"10.1016","volume":"36","author":[{"given":"Joshua","family":"Osowicki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Vekemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Kaslow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin H.","family":"Friede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew C.","family":"Steer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.vaccine.2018.02.068_b0005","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1016\/j.vaccine.2016.03.073","article-title":"Status of research and development of vaccines for Streptococcus pyogenes","volume":"34","author":"Steer","year":"2016","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2018.02.068_b0010","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7774\/cevr.2016.5.2.101","article-title":"Accelerating the development of a group A Streptococcus vaccine: an urgent public health need","volume":"5","author":"Excler","year":"2016","journal-title":"Clin Exp Vaccine Res"},{"key":"10.1016\/j.vaccine.2018.02.068_b0015","unstructured":"Dale JB, Batzloff MR, Cleary PP, Courtney HS, Good MF, Grandi G, et al. Current Approaches to Group A Streptococcal Vaccine Development. In: Ferretti JJ, Stevens DL, Fischetti VA, editors. Streptococcus pyogenes: Basic Biology to Clinical Manifestations. Oklahoma City (OK); 2016."},{"issue":"16","key":"10.1016\/j.vaccine.2018.02.068_b0020","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.vaccine.2017.02.060","article-title":"Clinical development strategy for a candidate group A streptococcal vaccine","volume":"35","author":"Schodel","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.068_b0025","series-title":"Update: Vaccine development for group A Streptococcus [Internet]","author":"Steer","year":"2017"},{"key":"10.1016\/j.vaccine.2018.02.068_b0030","unstructured":"Sims Sanyahumbi A, Colquhoun S, Wyber R, Carapetis JR. Global Disease Burden of Group A Streptococcus. In: Ferretti JJ, Stevens DL, Fischetti VA, editors. Streptococcus pyogenes: Basic Biology to Clinical Manifestations. Oklahoma City (OK); 2016."},{"issue":"11","key":"10.1016\/j.vaccine.2018.02.068_b0035","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","article-title":"The global burden of group A streptococcal diseases","volume":"5","author":"Carapetis","year":"2005","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2018.02.068_b0040","doi-asserted-by":"crossref","first-page":"e0136789","DOI":"10.1371\/journal.pone.0136789","article-title":"The global epidemiology of impetigo: a systematic review of the population prevalence of impetigo and pyoderma","volume":"10","author":"Bowen","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vaccine.2018.02.068_b0045","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3201\/eid2202.151358","article-title":"Invasive group A streptococcus infection among children Rural Kenya","volume":"22","author":"Seale","year":"2016","journal-title":"Emerging Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2018.02.068_b0050","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1017\/S095026880700917X","article-title":"High burden of invasive beta-haemolytic streptococcal infections in Fiji","volume":"136","author":"Steer","year":"2008","journal-title":"Epidemiol Infect"},{"issue":"2","key":"10.1016\/j.vaccine.2018.02.068_b0055","doi-asserted-by":"crossref","first-page":"e010248","DOI":"10.1136\/bmjopen-2015-010248","article-title":"Rationale and design of the African group A streptococcal infection registry: the AFROStrep study","volume":"6","author":"Barth","year":"2016","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.vaccine.2018.02.068_b0060","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1056\/NEJMoa1603693","article-title":"Global, regional, and national burden of rheumatic heart disease, 1990\u20132015","volume":"377","author":"Watkins","year":"2017","journal-title":"N Engl J Med"},{"issue":"5 Suppl 1","key":"10.1016\/j.vaccine.2018.02.068_b0065","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/INF.0000000000001098","article-title":"Opening the Black Box for Etiology of Neonatal Infections in High Burden Settings: The Contribution of ANISA","volume":"35","author":"Lawn","year":"2016","journal-title":"Pediatr Infect Dis J."},{"issue":"19","key":"10.1016\/j.vaccine.2018.02.068_b0070","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCULATIONAHA.116.024769","article-title":"Clinical outcomes in 3343 children and adults with rheumatic heart disease from 14 low- and middle-income countries: two-year follow-up of the global rheumatic heart disease registry (the REMEDY study)","volume":"134","author":"Zuhlke","year":"2016","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.vaccine.2018.02.068_b0075","doi-asserted-by":"crossref","first-page":"e0004033","DOI":"10.1371\/journal.pntd.0004033","article-title":"Rheumatic heart disease-attributable mortality at ages 5\u201369 years in Fiji: a five-year, national, population-based record-linkage cohort study","volume":"9","author":"Parks","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2018.02.068_b0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4269\/ajtmh.16-0302","article-title":"Precisely tracking childhood death","volume":"97","author":"Farag","year":"2017","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"10.1016\/j.vaccine.2018.02.068_b0085","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/jpids\/piu030","article-title":"The group A streptococcal carrier state reviewed: still an enigma","volume":"3","author":"DeMuri","year":"2014","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"10","key":"10.1016\/j.vaccine.2018.02.068_b0090","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1093\/cid\/cis629","article-title":"Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America","volume":"55","author":"Shulman","year":"2012","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America."},{"key":"10.1016\/j.vaccine.2018.02.068_b0095","unstructured":"Martin J. The Streptococcus pyogenes Carrier State. In: Ferretti JJ, Stevens DL, Fischetti VA, editors. Streptococcus pyogenes: Basic Biology to Clinical Manifestations. Oklahoma City (OK); 2016."},{"issue":"3","key":"10.1016\/j.vaccine.2018.02.068_b0100","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/INF.0000000000001413","article-title":"The cape town clinical decision rule for streptococcal pharyngitis in children","volume":"36","author":"Engel","year":"2017","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"10.1016\/j.vaccine.2018.02.068_b0105","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/INF.0b013e318194b2af","article-title":"Prospective surveillance of streptococcal sore throat in a tropical country","volume":"28","author":"Steer","year":"2009","journal-title":"Pediatr Infect Dis J."},{"issue":"5","key":"10.1016\/j.vaccine.2018.02.068_b0110","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1542\/peds.2006-3368","article-title":"Burden of acute sore throat and group A streptococcal pharyngitis in school-aged children and their families in Australia","volume":"120","author":"Danchin","year":"2007","journal-title":"Pediatrics."},{"issue":"4","key":"10.1016\/j.vaccine.2018.02.068_b0115","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10096-014-2274-9","article-title":"Evidence of streptococcal origin of acute non-necrotising cellulitis: a serological study","volume":"34","author":"Karppelin","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2018.02.068_b0120","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/ki.2011.478","article-title":"Post-streptococcal glomerulonephritis is a strong risk factor for chronic kidney disease in later life","volume":"81","author":"Hoy","year":"2012","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.vaccine.2018.02.068_b0125","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-0484","article-title":"Burden and economic cost of group A streptococcal pharyngitis","volume":"121","author":"Pfoh","year":"2008","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.vaccine.2018.02.068_b0130","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1186\/s12879-016-1990-4","article-title":"The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis","volume":"16","author":"Michaelidis","year":"2016","journal-title":"BMC infectious diseases."},{"issue":"3","key":"10.1016\/j.vaccine.2018.02.068_b0135","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/fampra\/cmw019","article-title":"Necessity of office visits for acute respiratory infections in primary care","volume":"33","author":"Renati","year":"2016","journal-title":"Fam Pract"},{"issue":"1","key":"10.1016\/j.vaccine.2018.02.068_b0140","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jamainternmed.2013.11673","article-title":"Antibiotic prescribing to adults with sore throat in the United States, 1997\u20132010","volume":"174","author":"Barnett","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.vaccine.2018.02.068_b0145","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/fampra\/cmw014","article-title":"Antibiotic prescribing for sore throat: a cross-sectional analysis of the ReCEnT study exploring the habits of early-career doctors in family practice","volume":"33","author":"Dallas","year":"2016","journal-title":"Fam Pract"},{"issue":"10","key":"10.1016\/j.vaccine.2018.02.068_b0150","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1473-3099(09)70178-1","article-title":"Global emm type distribution of group A streptococci: systematic review and implications for vaccine development","volume":"9","author":"Steer","year":"2009","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2018.02.068_b0155","doi-asserted-by":"crossref","first-page":"E222","DOI":"10.1111\/1469-0691.12134","article-title":"Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study","volume":"19","author":"McMillan","year":"2013","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"10.1016\/j.vaccine.2018.02.068_b0160","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1093\/cid\/ciu490","article-title":"The emm-cluster typing system for Group A Streptococcus identifies epidemiologic similarities across the Pacific region","volume":"59","author":"Baroux","year":"2014","journal-title":"Clin Infect Dis: Official Publ. Infect Dis Soc Am"},{"issue":"1","key":"10.1016\/j.vaccine.2018.02.068_b0165","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.vaccine.2016.11.065","article-title":"Structure-based design of broadly protective group a streptococcal M protein-based vaccines","volume":"35","author":"Dale","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.068_b0170","doi-asserted-by":"crossref","first-page":"e3226","DOI":"10.7717\/peerj.3226","article-title":"Whole genome sequencing of group A Streptococcus: development and evaluation of an automated pipeline for emmgene typing","volume":"5","author":"Kapatai","year":"2017","journal-title":"Peer J"},{"issue":"2","key":"10.1016\/j.vaccine.2018.02.068_b0175","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/CMR.00101-13","article-title":"Disease manifestations and pathogenic mechanisms of Group A Streptococcus","volume":"27","author":"Walker","year":"2014","journal-title":"Clin Microbiol Rev"},{"issue":"12","key":"10.1016\/j.vaccine.2018.02.068_b0180","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1111\/cmi.12531","article-title":"Streptococcal toxins: role in pathogenesis and disease","volume":"17","author":"Barnett","year":"2015","journal-title":"Cell Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2018.02.068_b0185","doi-asserted-by":"crossref","first-page":"e0119727","DOI":"10.1371\/journal.pone.0119727","article-title":"Innate immune response to Streptococcus pyogenes depends on the combined activation of TLR13 and TLR2","volume":"10","author":"Fieber","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.vaccine.2018.02.068_b0190","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1159\/000430498","article-title":"Group A streptococcus modulates host inflammation by manipulating polymorphonuclear leukocyte cell death responses","volume":"7","author":"Tsatsaronis","year":"2015","journal-title":"J Innate Immun"},{"issue":"21","key":"10.1016\/j.vaccine.2018.02.068_b0195","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1002\/1873-3468.12254","article-title":"Streptococcus pyogenes adhesion and colonization","volume":"590","author":"Brouwer","year":"2016","journal-title":"FEBS Lett"},{"key":"10.1016\/j.vaccine.2018.02.068_b0200","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3389\/fmicb.2016.00342","article-title":"The association between invasive group A streptococcal diseases and viral respiratory tract infections","volume":"7","author":"Herrera","year":"2016","journal-title":"Front Microbiol"},{"issue":"6","key":"10.1016\/j.vaccine.2018.02.068_b0205","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00207-16","article-title":"A Two-component regulatory system impacts extracellular membrane-derived vesicle production in group A Streptococcus","volume":"7","author":"Resch","year":"2016","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2018.02.068_b0210","doi-asserted-by":"crossref","first-page":"167089","DOI":"10.1155\/2015\/167089","article-title":"Correlates of protection for M protein-based vaccines against group A streptococcus","volume":"2015","author":"Tsoi","year":"2015","journal-title":"J Immunol Res."},{"issue":"19","key":"10.1016\/j.vaccine.2018.02.068_b0215","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1136\/heartjnl-2015-309188","article-title":"An immunological perspective on rheumatic heart disease pathogenesis: more questions than answers","volume":"102","author":"Bright","year":"2016","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.vaccine.2018.02.068_b0220","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/cid\/ciw248","article-title":"Epidemiology of invasive group A Streptococcal Infections in the United States, 2005\u20132012","volume":"63","author":"Nelson","year":"2016","journal-title":"Clin Infect Dis: Official Publ Infect Dis Soc Am"},{"issue":"22","key":"10.1016\/j.vaccine.2018.02.068_b0225","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.vaccine.2017.04.032","article-title":"Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: a systematic review of the literature","volume":"35","author":"Tsaban","year":"2017","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2018.02.068_b0230","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/jpids\/piw070","article-title":"Prospective longitudinal analysis of immune responses in pediatric subjects after pharyngeal acquisition of group A Streptococci","volume":"6","author":"Hysmith","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2018.02.068_b0235","doi-asserted-by":"crossref","first-page":"14946","DOI":"10.1038\/ncomms14946","article-title":"Association between a common immunoglobulin heavy chain allele and rheumatic heart disease risk in Oceania","volume":"8","author":"Parks","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2018.02.068_b0240","unstructured":"Watson ME, Jr, Neely MN, Caparon MG. Animal Models of Streptococcus pyogenes Infection. In: Ferretti JJ, Stevens DL, Fischetti VA, editors. Streptococcus pyogenes: Basic Biology to Clinical Manifestations. Oklahoma City (OK); 2016."},{"issue":"3","key":"10.1016\/j.vaccine.2018.02.068_b0245","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00618-16","article-title":"Differing efficacies of lead group A streptococcal vaccine candidates and full-length M protein in cutaneous and invasive disease models","volume":"7","author":"Rivera-Hernandez","year":"2016","journal-title":"mBio"},{"issue":"12","key":"10.1016\/j.vaccine.2018.02.068_b0250","doi-asserted-by":"crossref","first-page":"e1006122","DOI":"10.1371\/journal.ppat.1006122","article-title":"Streptococcal immunity Is constrained by lack of immunological memory following a single episode of pyoderma","volume":"12","author":"Pandey","year":"2016","journal-title":"PLoS Pathog"},{"issue":"3","key":"10.1016\/j.vaccine.2018.02.068_b0255","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/infdis\/173.3.619","article-title":"Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure","volume":"173","author":"Stevens","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.068_b0260","first-page":"255","article-title":"A non-human primate model of acute group a Streptococcus pharyngitis","volume":"431","author":"Sumby","year":"2008","journal-title":"Methods Mol Biol"},{"issue":"8","key":"10.1016\/j.vaccine.2018.02.068_b0265","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1172\/JCI107372","article-title":"Protective study with a group A streptococcal M protein vaccine. Infectivity challenge of human volunteers","volume":"52","author":"Fox","year":"1973","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.vaccine.2018.02.068_b0270","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/infdis\/131.3.217","article-title":"Protective studies with a group A streptococcal M protein vaccine. II. Challange of volenteers after local immunization in the upper respiratory tract","volume":"131","author":"Polly","year":"1975","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2018.02.068_b0275","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/infdis\/138.6.712","article-title":"Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with Type 3 or Type 12 group A Streptococcus","volume":"138","author":"D'Alessandri","year":"1978","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2018.02.068_b0280","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/jama.1969.03150190037007","article-title":"Rheumatic fever following streptococcal vaccination Report of three cases","volume":"207","author":"Massell","year":"1969","journal-title":"Jama"},{"issue":"7","key":"10.1016\/j.vaccine.2018.02.068_b0285","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1473-3099(15)00068-7","article-title":"Design, recruitment, and microbiological considerations in human challenge studies","volume":"15","author":"Darton","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2018.02.068_b0290","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/phe\/phv026","article-title":"Ethical criteria for human challenge studies in infectious diseases","volume":"9","author":"Bambery","year":"2016","journal-title":"Publ Health Ethics"},{"issue":"4","key":"10.1016\/j.vaccine.2018.02.068_b0295","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1128\/IAI.70.4.2171-2177.2002","article-title":"Immunogenicity of a 26-valent group A streptococcal vaccine","volume":"70","author":"Hu","year":"2002","journal-title":"Infection and immunity."},{"issue":"2","key":"10.1016\/j.vaccine.2018.02.068_b0300","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00457-16","article-title":"Assignment of opsonic values to pneumococcal reference Serum 007sp for use in opsonophagocytic assays for 13 serotypes","volume":"24","author":"Burton","year":"2017","journal-title":"Clin Vaccine Immunol: CVI"},{"issue":"2","key":"10.1016\/j.vaccine.2018.02.068_b0305","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1128\/CVI.13.2.165-169.2006","article-title":"Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines","volume":"13","author":"Romero-Steiner","year":"2006","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2018.02.068_b0310","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.mimet.2017.01.010","article-title":"Development of a high-throughput opsonophagocytic assay for the determination of functional antibody activity against Streptococcus pyogenes using bioluminescence","volume":"134","author":"Lorenz","year":"2017","journal-title":"J Microbiol Methods"},{"issue":"6","key":"10.1016\/j.vaccine.2018.02.068_b0315","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.tim.2010.02.007","article-title":"The streptococcal M protein: a highly versatile molecule","volume":"18","author":"Smeesters","year":"2010","journal-title":"Trends Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2018.02.068_b0320","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/art.1780100311","article-title":"Prospects for a vaccine against group A streptococci: the problem of the immunology of M proteins","volume":"10","author":"Stollerman","year":"1967","journal-title":"Arthrit Rheumatism"},{"issue":"11","key":"10.1016\/j.vaccine.2018.02.068_b0325","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/0264-410X(91)90216-S","article-title":"Group A streptococcal antigens and vaccine potential","volume":"9","author":"Kehoe","year":"1991","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.02.068_b0330","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1128\/CMR.13.3.470","article-title":"Pathogenesis of group A streptococcal infections","volume":"13","author":"Cunningham","year":"2000","journal-title":"Clin Microbiol Rev"},{"issue":"8","key":"10.1016\/j.vaccine.2018.02.068_b0335","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1086\/444458","article-title":"Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers","volume":"41","author":"McNeil","year":"2005","journal-title":"Clin Infect Dis: Official Publ Infect Dis Soc Am"},{"issue":"46","key":"10.1016\/j.vaccine.2018.02.068_b0340","doi-asserted-by":"crossref","first-page":"8175","DOI":"10.1016\/j.vaccine.2011.09.005","article-title":"New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci","volume":"29","author":"Dale","year":"2011","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2018.02.068_b0345","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1086\/374800","article-title":"Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection","volume":"187","author":"Batzloff","year":"2003","journal-title":"J Infect Dis"},{"issue":"31","key":"10.1016\/j.vaccine.2018.02.068_b0350","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1016\/j.vaccine.2010.05.018","article-title":"Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes","volume":"28","author":"Penfound","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.068_b0355","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-0-387-73960-1_5","article-title":"Current status of group A streptococcal vaccine development","volume":"609","author":"Dale","year":"2008","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"10.1016\/j.vaccine.2018.02.068_b0360","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/infdis\/jiu260","article-title":"A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development","volume":"210","author":"Sanderson-Smith","year":"2014","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2018.02.068_b0365","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jinf.2016.02.002","article-title":"Development of a multicomponent vaccine for Streptococcus pyogenes based on the antigenic targets of IVIG","volume":"72","author":"Reglinski","year":"2016","journal-title":"J Infect"},{"issue":"3","key":"10.1016\/j.vaccine.2018.02.068_b0370","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1208\/s12248-017-0069-5","article-title":"Evaluation of the potency, neutralizing antibody response, and stability of a recombinant fusion protein vaccine for streptococcus pyogenes","volume":"19","author":"Burlet","year":"2017","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.vaccine.2018.02.068_b0375","doi-asserted-by":"crossref","first-page":"45","DOI":"10.7774\/cevr.2017.6.1.45","article-title":"Trivalent M-related protein as a component of next generation group A streptococcal vaccines","volume":"6","author":"Courtney","year":"2017","journal-title":"Clin Exp Vaccine Res"},{"issue":"4","key":"10.1016\/j.vaccine.2018.02.068_b0380","doi-asserted-by":"crossref","first-page":"e0175707","DOI":"10.1371\/journal.pone.0175707","article-title":"Local Th17\/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes","volume":"12","author":"Mortensen","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vaccine.2018.02.068_b0385","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.vaccine.2016.11.040","article-title":"Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens","volume":"35","author":"Maruggi","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.068_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2017.05.030","article-title":"A critical role of zinc importer AdcABC in group A streptococcus-host interactions during infection and its implications for vaccine development","author":"Makthal","year":"2017","journal-title":"EBioMed"},{"key":"10.1016\/j.vaccine.2018.02.068_b0395","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.201600639","article-title":"Synthesis, characterization and immunological evaluation of self-adjuvanting group a streptococcal vaccine candidates bearing various lipidic adjuvanting moieties","author":"Fagan","year":"2017","journal-title":"Chembiochem: Eur J Chem Biol"},{"issue":"51","key":"10.1016\/j.vaccine.2018.02.068_b0400","doi-asserted-by":"crossref","first-page":"6472","DOI":"10.1016\/j.vaccine.2016.11.008","article-title":"Modular virus-like particles for sublingual vaccination against group A streptococcus","volume":"34","author":"Seth","year":"2016","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2018.02.068_b0405","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.4049\/jimmunol.1501994","article-title":"Combinatorial synthetic peptide vaccine strategy protects against hypervirulent CovR\/S mutant Streptococci","volume":"196","author":"Pandey","year":"2016","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"key":"10.1016\/j.vaccine.2018.02.068_b0410","doi-asserted-by":"crossref","first-page":"22030","DOI":"10.1038\/srep22030","article-title":"Identifying protective Streptococcus pyogenes vaccine antigens recognized by both B and T cells in human adults and children","volume":"6","author":"Mortensen","year":"2016","journal-title":"Sci Reports"},{"issue":"8","key":"10.1016\/j.vaccine.2018.02.068_b0415","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/1348-0421.12397","article-title":"Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen","volume":"60","author":"Mansour","year":"2016","journal-title":"Microbiol Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2018.02.068_b0420","doi-asserted-by":"crossref","first-page":"e0168861","DOI":"10.1371\/journal.pone.0168861","article-title":"Co-activation of Th17 and antibody responses provides efficient protection against mucosal infection by group A Streptococcus","volume":"11","author":"Chen","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.vaccine.2018.02.068_b0425","doi-asserted-by":"crossref","first-page":"16155","DOI":"10.1038\/nmicrobiol.2016.155","article-title":"Conserved patterns hidden within group A Streptococcus M protein hypervariability recognize human C4b-binding protein","volume":"1","author":"Buffalo","year":"2016","journal-title":"Nature Microbiol"},{"issue":"9","key":"10.1016\/j.vaccine.2018.02.068_b0430","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1128\/IAI.00295-10","article-title":"Novel conserved group A streptococcal proteins identified by the antigenome technology as vaccine candidates for a non-M protein-based vaccine","volume":"78","author":"Fritzer","year":"2010","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2018.02.068_b0435","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M111.015693","article-title":"Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case","volume":"11","author":"Bensi","year":"2012","journal-title":"Mol Cell Proteomics: MCP"},{"issue":"6","key":"10.1016\/j.vaccine.2018.02.068_b0440","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1586\/erv.09.33","article-title":"Moving forward: a mucosal vaccine against group A streptococcus","volume":"8","author":"Georgousakis","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"101","key":"10.1016\/j.vaccine.2018.02.068_b0445","first-page":"313","article-title":"The contribution of non-human primate models to the development of human vaccines","volume":"18","author":"Rivera-Hernandez","year":"2014","journal-title":"Discov Med"},{"issue":"10031","key":"10.1016\/j.vaccine.2018.02.068_b0450","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/S0140-6736(16)30394-4","article-title":"Mind the gap: jumping from vaccine licensure to routine use","volume":"387","author":"O'Brien","year":"2016","journal-title":"Lancet (London, England)"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1830255X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1830255X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T05:46:25Z","timestamp":1569217585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1830255X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":90,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0264410X1830255X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.068","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}